اخبار و اعلانات

 آمار

تعداد نشریات285
تعداد نشریات سازمان83
تعداد شماره‌ها3,084
تعداد مقالات34,412
تعداد مشاهده مقاله48,551,864
تعداد دریافت فایل اصل مقاله79,137,159
Parsa, Nasrin, Salarilak, Shaker, Mohammad, Heidari. (1404). Effectiveness of COVID-19 Vaccines in Mahabad, Iran: A Cohort Study. سامانه مدیریت نشریات علمی, 80(3), 615-622. doi: 10.32592/ARI.2025.80.3.615
Nasrin Parsa; Shaker Salarilak; Heidari Mohammad. "Effectiveness of COVID-19 Vaccines in Mahabad, Iran: A Cohort Study". سامانه مدیریت نشریات علمی, 80, 3, 1404, 615-622. doi: 10.32592/ARI.2025.80.3.615
Parsa, Nasrin, Salarilak, Shaker, Mohammad, Heidari. (1404). 'Effectiveness of COVID-19 Vaccines in Mahabad, Iran: A Cohort Study', سامانه مدیریت نشریات علمی, 80(3), pp. 615-622. doi: 10.32592/ARI.2025.80.3.615
Parsa, Nasrin, Salarilak, Shaker, Mohammad, Heidari. Effectiveness of COVID-19 Vaccines in Mahabad, Iran: A Cohort Study. سامانه مدیریت نشریات علمی, 1404; 80(3): 615-622. doi: 10.32592/ARI.2025.80.3.615

Effectiveness of COVID-19 Vaccines in Mahabad, Iran: A Cohort Study

Archives of Razi Institute
مقاله 9، دوره 80، شماره 3، مرداد و شهریور 2025، صفحه 615-622    اصل مقاله (401.1 K)
نوع مقاله: Original Articles
شناسه دیجیتال (DOI): 10.32592/ARI.2025.80.3.615
نویسندگان
Nasrin Parsa1؛ Shaker Salarilak1؛ Heidari Mohammad* 2
1Department of Epidemiology and Biostatistics, School of Medicine, Urmia University of Medical Sciences, Urmia, Iran.
2Assistant Professor of Epidemiology Department of Epidemiology and Biostatistics School Of Medicine Urmia University Of Medical Sciences Urmia , Iran.
چکیده
The COVID-19 pandemic has shown that infectious diseases can become serious crises, emphasizing the importance of vaccination as the best way to prevent such outbreaks. The aim of study was to examine how well COVID-19 vaccines work in the northwestern region of Iran, city of Mahabad.This retrospective cohort study compared 1077 vaccinated employees of the Mahabad city health department (exposed group) with 1338 unvaccinated employees from other departments (unexposed group). Demographic details, vaccination dates, types, and outcomes were extracted from the local health system. Data on cases came from the disease unit, while hospitalization was retrieved from the Medical Care Monitoring Center (MCMC). Attributable fractions for the exposed group and relative risks with 95% confidence intervals were calculated for each vaccine dose, stratified by sex, age group, and exposure level. Data analysis was conducted using STATA16, with a p-value < 0.05 considered statistically significant.The overall efficacy of COVID-19 vaccines in preventing the disease is 51%, with a 26% effectiveness in averting hospitalization. Stratifying by vaccine type, AstraZeneca exhibits an 81% efficacy (95% CI: 0.61–0.91) in preventing infection, followed by Sputnik at 41% (95% CI: 0.086–0.62) and Sinopharm-Baharat at 10% (95% CI: 0.50–0.46). Similarly, in preventing hospitalization, AstraZeneca demonstrates a 79% efficacy (95% CI: 0.083–0.95), Sputnik at 29% (95% CI: 0.77–0.71), and Sinopharm–Bharat at 44% (95% CI: 0.63–0.81). Notably, effectiveness in preventing both disease and hospitalization is higher in men than women. AstraZeneca vaccine emerges as the most effective in preventing both disease and hospitalization, followed by Sputnik with optimal efficacy. Analyzing vaccine effectiveness across age groups reveals the lowest efficacy in individuals below 30 years old, while the highest efficacy is observed in the age group above 51 years. Despite challenges in vaccine selection and timely administration in Iran, our findings demonstrate that three doses of COVID-19 vaccines achieve an effectiveness exceeding 75% for preventing hospitalization and death, underscoring the vital role of vaccination as a primary preventive measure against infectious disease outbreaks. This reinforces the importance of proactive preparation and investment in robust vaccination programs for optimal epidemic control.
کلیدواژه‌ها
COVID-19 Vaccines؛ Vaccine Efficacy؛ Risk Assessment؛ Risk Ratio؛ Iran
عنوان مقاله [English]
اثربخشی واکسن های کوید-19 در مهاباد ایران : مطالعه کوهورت
چکیده [English]
همه‌گیری COVID-19 نشان داده است که بیماری‌های عفونی می‌توانند به بحران‌های جدی تبدیل شوند و بر اهمیت واکسیناسیون به‌عنوان بهترین راه برای جلوگیری از چنین شیوع‌هایی تأکید دارد. هدف از این مطالعه بررسی میزان عملکرد واکسن کووید-19 در منطقه شمال غرب ایران، شهر مهاباد بود. این مطالعه همگروهی گذشته نگر، 1077 کارمند واکسینه شده اداره بهداشت شهرستان مهاباد (گروه مواجهه) را با 1338 کارمند واکسینه نشده سایر ادارات(گروه بدون مواجهه) مقایسه کرد. اطلاعات دموگرافیک، تاریخ واکسیناسیون، انواع و نتایج از سیستم بهداشتی محلی استخراج شد. داده‌های مربوط به موارد از واحد بیماری گرفته شد، در حالی که بستری شدن در بیمارستان از مرکز نظارت بر مراقبت‌های پزشکی (MCMC) بازیابی شد. کسرهای قابل انتساب برای گروه در معرض خطر و خطرات نسبی با فواصل اطمینان 95 درصد برای هر دوز واکسن، طبقه بندی شده بر اساس جنس، گروه سنی و سطح مواجهه محاسبه شد. تجزیه و تحلیل داده‌ها با استفاده از STATA16 انجام شد که مقدار p
مراجع
  1. Wu D, Wu T, Liu Q, Yang Z. The SARS-CoV-2 outbreak: what we know. International journal of infectious diseases. 2020;94:44-8.
  2. Sohrabi C, Alsafi Z, O''neill N, Khan M, Kerwan A, Al-Jabir A, et al. World Health Organization declares global emergency: A review of the 2019 novel coronavirus (COVID-19). International journal of surgery. 2020;76:71-6.
  3. Maghded HS, Ghafoor KZ, Sadiq AS, Curran K, Rawat DB, Rabie K, editors. A novel AI-enabled framework to diagnose coronavirus COVID-19 using smartphone embedded sensors: design study. 2020 IEEE 21st international conference on information reuse and integration for data science (IRI); 2020: IEEE.
  4. Jalali Farahani A, Ashourzadeh Fallah S, Khashei Z, Heidarzadeh F, Sadeghi F, Masoudi P, et al. Available effective vaccines in preventing COVID-19: a narrative review. Journal of Marine Medicine. 2021;3(4):153-62.
  5. Gao Q, Bao L, Mao H, Wang L, Xu K, Yang M, et al. Development of an inactivated vaccine candidate for SARS-CoV-2. Science. 2020;369(6499):77-81.
  6. Mirahmadizadeh A, Heiran A, Bagheri Lankarani K, Serati M, Habibi M, Eilami O, et al., editors. Effectiveness of coronavirus disease 2019 vaccines in preventing infection, hospital admission, and death: a historical cohort study using Iranian registration data during vaccination program. Open forum infectious diseases; 2022: Oxford University Press US.
  7. Florez H, Singh S. Online dashboard and data analysis approach for assessing COVID-19 case and death data. F1000Research. 2020;9:570.
  8. Jara A, Undurraga EA, González C, Paredes F, Fontecilla T, Jara G, et al. Effectiveness of an inactivated SARS-CoV-2 vaccine in Chile. New England Journal of Medicine. 2021;385(10):875-84.
  9. Nasreen S, Chung H, He S, Brown KA, Gubbay JB, Buchan SA, et al. Effectiveness of COVID-19 vaccines against symptomatic SARS-CoV-2 infection and severe outcomes with variants of concern in Ontario. Nature microbiology. 2022;7(3):379-85.
  10. Ittefaq M, Baines A, Abwao M, Shah SFA, Ramzan T. “Does Pakistan still have polio cases?”: Exploring discussions on polio and polio vaccine in online news comments in Pakistan. Vaccine. 2021;39(3):480-6.
  11. Wong L, Wong P, AbuBakar S. Vaccine hesitancy and the resurgence of vaccine preventable diseases: the way forward for Malaysia, a Southeast Asian country. Human vaccines & immunotherapeutics. 2020;16(7):1511-20.
  12. Oliver SE. The advisory committee on immunization practices’ interim recommendation for use of Pfizer-BioNTech COVID-19 vaccine—United States, December 2020. MMWR Morbidity and mortality weekly report. 2020;69.
  13. Silva-Valencia J, Soto-Becerra P, Escobar-Agreda S, Fernandez-Navarro M, Moscoso-Porras M, Solari L, et al. Effectiveness of the BBIBP-CorV vaccine in preventing infection and death in health care workers in Peru 2021. Travel Medicine and Infectious Disease. 2023;53:102565.
  14. Li X-N, Huang Y, Wang W, Jing Q-L, Zhang C-H, Qin P-Z, et al. Effectiveness of inactivated SARS-CoV-2 vaccines against the Delta variant infection in Guangzhou: a test-negative case–control real-world study. Emerging microbes & infections. 2021;10(1):1751-9.
  15. González S, Olszevicki S, Salazar M, Calabria A, Regairaz L, Marín L, et al. Effectiveness of the first component of Gam-COVID-Vac (Sputnik V) on reduction of SARS-CoV-2 confirmed infections, hospitalisations and mortality in patients aged 60-79: a retrospective cohort study in Argentina. EClinicalMedicine. 2021;40.
  16. Heidarzadeh A, Moridani MA, Khoshmanesh S, Kazemi S, Hajiaghabozorgi M, Karami M. Effectiveness of COVID-19 vaccines on hospitalization and death in Guilan, Iran: a test-negative case-control study. International Journal of Infectious Diseases. 2023;128:212-22.
  17. Nguyen LBL, Bauer R, Lesieur Z, Galtier F, Duval X, Vanhems P, et al. Vaccine effectiveness against COVID-19 hospitalization in adults in France: A test negative case control study. Infectious Diseases Now. 2022;52(1):40-3.
  18. Varghaei A, Heidari M, Daneshyar C, Nouri A, Mikaeilvand A. Side Effects of Sputnik V Vaccine in the Medical Staff of Dedicated COVID-19 Hospital. Iranian Journal of Medical Sciences. 2023;48(4):430.
آمار
تعداد مشاهده مقاله: 397
تعداد دریافت فایل اصل مقاله: 502


counter
سامانه مدیریت نشریات علمی. طراحی و پیاده سازی از سیناوب